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Based on molecular mechanisms and physiologic data, a strong association has 
been established between dysregulated systemic inflammation and progression 
of acute respiratory distress syndrome (ARDS). In ARDS patients, glucocorticoid 
receptor-mediated downregulation of systemic inflammation is essential to restore 
homeostasis, decrease morbidity and improve survival and can be significantly 
enhanced with prolonged low-to-moderate dose glucocorticoid treatment. A large 
body of evidence supports a strong association between prolonged glucocorticoid 
treatment-induced downregulation of the inflammatory response and improvement 
in pulmonary and extrapulmonary physiology. The balance of the available data 
from eight controlled trials (n =  622) provides consistent strong level of evidence 
for improving patient-centered outcomes and hospital survival. The sizable increase 
in mechanical ventilation-free days (weighted mean difference, 6.48  days; CI 95% 
2.57–10.38, p < 0.0001) and intensive care unit-free days (weighted mean difference, 
7.7 days; 95% CI, 3.13–12.20, p < 0.0001) by day 28 is superior to any investigated 
intervention in ARDS. For treatment initiated before day 14 of ARDS, the increased in 
hospital survival (70 vs. 52%, OR 2.41, CI 95% 1.50–3.87, p = 0.0003) translates into 
a number needed to treat to save one life of 5.5. Importantly, prolonged glucocorti-
coid treatment is not associated with increased risk for nosocomial infections (22 vs. 
27%, OR 0.61, CI 95% 0.35–1.04, p = 0.07). Treatment decisions involve a tradeoff 
between benefits and risks, as well as costs. This low-cost, highly effective therapy 
is familiar to every physician and has a low risk profile when secondary prevention 
measures are implemented.
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PHYSiOLOGiC CONSiDeRATiONS FOR PROLONGeD 
GLUCOCORTiCOiD THeRAPY iN ARDS
Acute respiratory distress syndrome (ARDS) is a secondary disease that follows – usually within 
6–48 h – a primary disease of multifactorial etiology (most frequently pneumonia and extrapulmo-
nary sepsis) associated with severe systemic inflammation. Inflammatory mediators released into the 
systemic circulation (systemic inflammation) from the site of infection reach the broad pulmonary 
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capillary surface producing severe and diffuse inflammatory 
exudate of the pulmonary lobules resulting in hypoxemic respira-
tory failure (1, 2). In sepsis and ARDS, systemic inflammation 
is activated by the nuclear factor-κB (NF-κB) signaling system 
and downregulated by the activated glucocorticoid receptor-α 
(GRα) (1) (Figure 1). In these patients, inadequate (endogenous 
glucocorticoid activated) GRα-mediated downregulation of 
pro-inflammatory NF-κB in circulating and tissue cells leads to 
higher initial levels and persistent elevation over time in plasma 
and bronchoalveolar lavage (BAL) markers of inflammation, 
hemostasis, and tissue repair (1).
In ARDS, “resolution of inflammation and restoration of 
tissue homeostasis is an active, continuous, and coordinated 
process (switch from production of pro-inflammatory toward 
pro-resolving molecules)” (16) – characterized by non-phlogistic 
elimination of granulocytes by apoptosis, restoration of the 
alveolar-capillary membrane’s integrity, resorption of edema, 
increased surfactant production, decreased clotting, and fibro-
proliferation with resolution of intra-alveolar and interstitial 
granulation tissue (1, 2) – that can be accelerated by prolonged 
glucocorticoid treatment (17). There is a strong scientific founda-
tion in support of prolonged methylprednisolone treatment in 
ARDS, with evidence showing that this treatment is directed at 
the core pathogenic mechanism of ARDS and as a result posi-
tively affects all “layers” – biology, histology, and physiology – of 
the disease process (18).
Importantly, in ARDS the inadequate GRα-mediated down-
regulation of pro-inflammatory transcription factor NF-κB 
in circulating and tissue cells leads to persistent elevation over 
time (>4 weeks) in plasma and BAL markers of inflammation, 
hemostasis, and tissue repair (maladaptive repair) (1). In experi-
mental sepsis, inhibition of endogenous glucocorticoid synthesis 
aggravates acute lung injury, while glucocorticoid treatment was 
associated with protection (19). Experimental ARDS is associ-
ated with a significant reduction in lung tissue GRα expression 
(20–22) and increase in GRβ mRNA (21), leading to decreased 
GRα nuclear translocation (21). In these experiments, low-
dose glucocorticoid treatment – contrary to placebo – restored 
GRα number and function, leading to resolution of pulmonary 
inflammation (22, 23). Moreover, alveolar macrophages extracted 
from patients with established ARDS have decreased 11β-HSD 
oxo-reductase activity with decreased conversion of cortisone to 
cortisol (24).
In an ex vivo study, prolonged methylprednisolone treat-
ment – contrary to placebo – was associated with upregulation 
in GRα number and nuclear translocation with reduction 
in NF-κB–DNA binding and transcription of inflammatory 
cytokines (25) (Figure  2). ARDS patients randomized to pro-
longed methylprednisolone treatment, contrary to placebo, 
demonstrated a sustained reduction in plasma and/or BAL levels 
of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 
(1), IL-8, soluble intercellular adhesion molecule-1 (1), procol-
lagen aminoterminal propeptide type I and III (1), indices of 
alveolar-capillary membrane permeability (BAL albumin, total 
protein, and percentage neutrophils) (26), and an increase in 
IL-10 (1), protein C (27), and surfactant (28).
PROLONGeD GLUCOCORTiCOiD 
TReATMeNT iN ARDS iS ASSOCiATeD 
wiTH iMPROveD ARDS OUTCOMeS: 
LeSSONS FROM ADULT ARDS STUDieS
The updated literature on prolonged glucocorticoid treatment in 
adult patients with ARDS includes eight published randomized 
controlled trials (RCTs): four investigated methylprednisolone 
treatment initiated in early (<72  h; n =  118) (29, 30) or late 
ARDS (day 5–28; n = 204) (31, 32), and four investigated 7 days 
of hydrocortisone treatment in early ARDS (n = 297) (33–36). 
Additional publications include, one RCT recently presented in 
abstract form (n = 197) (37), seven cohort studies with historical 
or concurrent control (38–44), and eight observational reports 
(45–52).
As shown in Table  1, glucocorticoid administration, in 
comparison to placebo, was associated with a significant down-
regulation of systemic inflammation [reduction in inflammatory 
cytokines (29, 31, 32, 34), protein C (27, 30), and/or C-reactive 
protein levels (29–31, 33, 35)]. This biological response was asso-
ciated with significant improvement in PaO2:FiO2 (29–36), and 
reduction in duration of mechanical ventilation (29–33, 35), and 
intensive care unit (ICU)-length of stay (1, 29, 30, 32, 33, 36). These 
consistently reproducible findings (29–36) “provide additional 
support for a causal relationship between reduction in systemic 
inflammation and resolution of ARDS that is further reinforced 
by experimental (53–56) and clinical (31, 38, 45, 46, 53, 57) data, 
showing that  rebound inflammation following early removal of 
glucocorticoid treatment leads to recrudescence of ARDS that 
improves with reinstitution of glucocorticoid therapy” (58).
In a recent systematic review (58), we evaluated the effective-
ness of prolonged glucocorticoid treatment in ARDS with two 
sets of intention-to-treat analyses: a primary analysis of indi-
vidual patients data (IPD) of the four methylprednisolone RCTs 
(n = 322) (29–32) and a trial-level meta-analysis incorporating 
methylprednisolone and hydrocortisone RCTs (n = 297) (33–36). 
In the primary IPD analysis, definitions were standardized to 
derive outcomes of four RCTs investigating methylprednisolone 
treatment initiated in early (<72 h; n = 118) (29, 30) and late (after 
5–7 days; n = 204) (1, 32) ARDS. In the early (29, 30) and late 
ARDS trials (31, 32), the initial daily methylprednisolone dosage 
was 1 and 2 mg/kg/day and duration of treatment extended up to 
25 and 32 days, respectively. Since these RCTs differed in timing 
of treatment initiation [early (29, 30) vs. late (31, 32)] and speed 
of drug tapering [slow (29–31) vs. rapid (32)] after achieving 
initial unassisted breathing (UAB), the IPD analysis evaluated 
the impact of these treatment characteristics on outcomes. As 
shown in Table 2, glucocorticoid administration, in comparison 
to placebo, was associated with accelerated resolution of ARDS 
improving a broad spectrum of interrelated clinical outcomes and 
decreasing hospital mortality and health-care utilization. “By day 
28, the methylprednisolone group achieved initial UAB earlier 
(12.4 ±  0.61 vs. 19.8 ±  0.78  days; HR 2.59, 95% CI 1.95–3.43, 
p <  0.001; Figure  3) and the effect was similar after adjusting 
for pre-specified covariates. Incorporating data past day 28, the 
FiGURe 1 | interaction between NF-κB and the activated glucocorticoid receptor. Reproduced from Ref. (3) with permission from S. Karger AG, Medical 
and Scientific Publishers (Allschwilerstrasse 10, 4009 Basel, Switzerland). When cells are stimulated by inflammatory signals, specific kinases phosphorylate the 
inhibitory protein IκB and cause its rapid degradation. The activated form of NF-κB then moves to the nucleus initiating the transcription of mRNA of 
inflammatory cytokines, chemokines, cell adhesion molecules, and inflammation-associated enzymes (cyclooxygenase, phospholipase A2, and inducible nitric 
oxide). Cortisol or exogenous glucocorticoids freely cross into the cytoplasm and bind to their specific glucocorticoid receptors (GRα) to form the activated 
receptor (GC-GRα). GC-GRα complexes may influence NF-κB activity in five major ways: (1) physically interacting with the p65 subunit with formation of an 
inactive (GC-GRα/NF-κB) complex (4, 5), (2) inducing the synthesis of the inhibitory protein IκBα via interaction with glucocorticoid-responsive element DNA in 
the promoter of the IκB gene (5–7), (3) blocking degradation of IκBα via enhanced synthesis of IL-10 (8–10), (4) impairing TNF-α-induced degradation of IκBα 
(11, 12), and (5) competing for limited amounts of GR coactivators, such as CREB-binding protein (CBP) and steroid receptor coactivator-1 (SRC-1) (13).  
 (Continued)
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TABLe 1 | Randomized trials investigating prolonged glucocorticoid treatment in early and late ARDS: level of significant difference (p value) – in 
comparison to control – for anti-inflammatory therapeutic effect and clinical–physiological parameters of disease resolution.
Study (n = 619) Reduction in markers of 
systemic inflammationa
improvement in 
PaO2:FiO2
Reduction in duration of 
assisted breathing
Reduction in iCU  
length of stay
Meduri et al. (31) (n = 24) 0.0001 0.001 0.001 0.005
Confalonieri et al. (33) (n = 34)b 0.01 0.001 0.007 0.001
Annane et al. (34) (n = 177) 0.01 0.001 Noc,d Not reported
Steinberg et al. (32) (n = 180) 0.001 0.02 0.001c 0.02c
Meduri et al. (29) (n = 91) 0.0001 0.006 0.002 0.007
Sabry and Omar (35) (n = 60)b 0.0001 0.001 0.01 Not reported
Liu et al.(36) (n = 26) Not reported Yes|| Not reported Yes||
Rezk and Ibrahim (30) (n = 27) 0.0001 0.001 0.001 0.001
Proportion of studies with significant difference 100% 100% 87% 100%
ICU, intensive care unit.
aGlucocorticoid administration was associated with a significant downregulation of systemic inflammation [reduction in inflammatory cytokines (29, 31, 32, 34), protein C (27, 30) 
and/or C-reactive protein levels (29–31, 33, 35)].
bThe data from Confalonieri et al. (33) and Sabry at al. (35) are limited to patients on assisted breathing.
cIn the randomized trials by Annane et al. (34) and Steinberg et al. (32), data were reported only as ventilator-free (32, 34) and ICU-free days to day 28 (32).
dIn the randomized trials by Annane (34), a significant (p = 0.006) reduction in ventilator-free days was observed only in the larger subgroup (N = 129) of non-responders to a short 
corticotropin test.
||p value not available.
FiGURe 2 | Longitudinal relation on natural logarithmic scales between mean levels of nuclear NF-κB and nuclear GRα: resolving vs. unresolving 
ARDS (left) and after randomization to methylprednisolone vs. placebo (right). Data shown are from Ref. (3, 25). Left: plasma samples from patients with 
sustained elevation in cytokine levels over time (triangles) elicited only a modest longitudinal increase in GC-GRα-mediated activity (P = 0.04) and a progressive 
significant (P = 0.0001) increase in NF-κB nuclear binding over time (dysregulated, NF-κB-driven response). In contrast, in patients with regulated inflammation 
(squares), an inverse relation was observed between these two transcription factors, with the longitudinal direction of the interaction shifting to the left (decreased 
NF-κB) and upward (increased GC-GRα). The first interaction is defined as NF-κB-driven response (progressive increase in NF-κB–DNA binding and transcription of 
TNF-α and IL-1β) and the second interaction as GRα-driven response (progressive increase in GRα-DNA binding and transcription of IL-10 and repression of TNF-α 
and IL-1β). Right: longitudinal relation on natural logarithmic scales between mean levels of nuclear NF-κB and nuclear GRα observed by exposing naive PBL to 
plasma samples collected at randomization (rand) and after 3, 5, 7, and 10 days in the methylprednisolone (squares) and placebo (triangles) groups. With 
methylprednisolone, contrary to placebo, the intracellular relation between the NF-κB and GRα signaling pathways changed from an initial NF-κB-driven and 
GR-resistant state to a GRα-driven and GR-sensitive one. It is important to compare the two figures to appreciate how methylprednisolone supplementation 
restored the equilibrium between activation and suppression of inflammation that is distinctive of a regulated inflammatory response.
IκBα, in addition to holding NF-κB in an inactive cytoplasmic state (5–7), also translocates into the nucleus, where it binds activated NF-κB complexes to induce their 
export to the cytoplasm (4). GC-GRα may also decrease the stability of mRNA of several inflammatory cytokines and other molecules (14). Products of the genes that 
are stimulated by NF-κB activate this transcription factor. Thus, both TNF-α and IL-1β activate and are activated by NF-κB, by forming a positive regulatory loop that 
amplifies and perpetuates inflammation (15). Regulated response: GC-GRα activation sufficient to maintain NF-κB levels in homeostasis and achieve a reduction in 
transcription of inflammatory mediators over time is shown. In ARDS improvers, both GC-GRα binding to NF-κB and nuclear GC-GRα binding increased significantly 
over time, indicating an excess activation of GC-GRα compared to NF-κB (GC-GRα-driven response). Dysregulated response: an excess of NF-κB activation is 
shown, leading to protracted transcription of inflammatory mediators over time. In ARDS non-improvers, GC-GRα binding to NF-κB was modestly increased while 
nuclear NF-κB binding increased substantially over time and nuclear GC-GRα and cytoplasmic IκBα levels declined (NF-κB-driven response).
FiGURe 1 | Continued
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FiGURe 4 | Probability of achieving unassisted breathing from 
randomization (methylprednisolone vs. placebo) to hospital discharge 
or day 28. Estimated cumulative incidence of achieving (initial) unassisted 
breathing by day 28 for patients with ARDS (n = 322) receiving either 
prolonged methylprednisolone treatment (blue solid line) or usual care (green 
dashed line). Death before achieving unassisted breathing is considered a 
competing risk. By day 28, the methylprednisolone group achieved initial 
UAB earlier (12.4 ± 0.61 vs. 19.8 ± 0.78 days; HR 2.59, 95% CI 1.95–3.43, 
p < 0.001). Reproduced with permission (58).
FiGURe 3 | Patients, in each trial, alive on study day 8, 15, 22, and 29 
that received at least 7, 14, 21, and 28 days of methylprednisolone 
treatment. N value within each column reports patients alive on the specified 
day. *P < 0.001 in comparison to the other three trials. Reproduced with 
permission (58).
TABLe 2 | effects of prolonged methylprednisolone treatment based on individual patient data from four randomized clinical trials of acute respiratory 
distress syndrome.
Outcome variables Methylprednisolone (N = 186) Placebo (N = 136) Odds ratio (95% Ci) or LS means 
difference (95% Ci)
Died before achieving initial UAB by day 28 – n (%) 23 (12) 39 (29) 0.35 (0.20, 0.63), p < 0.001
Alive on day 28 on initial AB with no UAB – n (%) 14 (8) 29 (21) 0.35 (0.173, 0.69), p = 0.003
Achieved initial UAB by day 28 – n (%) 149 (80) 68 (50%) 3.77 (2.29, 6.23), p < 0.001
Mechanical ventilation-free days by day 28 – mean ± SE 13.3 ± 11.8 7.6 ± 5.7 5.76 (3.76, 11.52), p < 0.001
Duration of initial AB including data past day 28 – mean ± SD 12.9 ± 13.4 23.0 ± 13.9 −10.10 (−13.12, −7.08), p < 0.001
Intensive care unit-free days up to day 28 – mean ± SE 10.8 ± 0.71 6.4 ± 0.85 4.45 (2.64, 6.26), p < 0.001
Hospital-free days up to day 28 – mean ± SE 7.0 ± 0.57 3.82 ± 0.68 3.19 (1.74, 4.64), p < 0.001
Hospital mortality – n (%) 37 (20) 45 (33) 0.48 (0.29, 0.81), p = 0.006
Hospital mortality for those randomized before ARDS  
day 14 (n = 272) – n (%)
32 (20) 43 (39) 0.39 (0.22, 0.67), p < 0.001
Reproduced with permission from Ref. (58).
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methylprednisolone group also had shorter duration of initial AB 
(12.9 ±  13.4 vs. 23.0 ±  13.9 days, mean difference −10.1, 95% 
−13.12 to 7.08, p < 0.001; high certainty) (58). In the trial-level 
meta-analysis, glucocorticoid treatment was associated with a 
sizable and significant increase in MV-free days (13.3 vs. 7.6 days; 
mean difference 5.76, 95% CI 3.76–11.52; high certainty), and in 
ICU-free days (10.8 vs. 6.4 days; mean difference 4.45, 95% CI 
2.64–6.26; moderate certainty)” (58).
Importantly, continuation of methylprednisolone administra-
tion after achieving UAB is essential to preserve the significant 
improvements achieved under treatment. The ARDS network 
trial (32), contrary to the other RCTs (29–31), had significantly 
(p < 0.001) shorter duration of treatment (Figure 4) as a result 
of rapid tapering soon after extubation (3.1 ±  1.1  days) (59). 
“The ARDS network trial (32), in comparison to the other trials 
(29–31), reported more methylprednisolone patients returning to 
AB (26 vs. 7%; p < 0.008) and to the ICU (21 vs. 2%; p = 0.007) 
by day 28. Return to AB (without reinstitution of glucocorticoid 
treatment in patients with adrenal suppression) was associated 
with higher hospital mortality (21 vs. 4%; p =  0.003), a factor 
recognized by the authors (32) to be an important reason why 
early significant physiological and survival (discharged home 
after initial wean: 62 vs. 49%, p =  0.006) (58) benefits did not 
translate into a 60-day survival (primary outcome) advantage.”
The ARDS network original report (32) found increased 
60-day mortality for methylprednisolone-treated patients ran-
domized after day 13 (32). “This subgroup (n =  48), however, 
had an uncharacteristically low mortality (8%) and large dif-
ferences in baseline characteristics (60). When the analysis was 
adjusted for the imbalances at baseline, the mortality difference 
lost significance (25.6 vs. 13.2%; p = 0.325) (61). Irrespective of 
the interpretation of these data, there is a broad consensus that if 
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glucocorticoid treatment is to be initiated, it should be initiated 
before day 14 of ARDS (62). For patients randomized before 
day 14 of ARDS onset, in the methylprednisolone trials, there 
was a 19% absolute reduction in hospital mortality (20 vs. 39%, 
p < 0.001) and a hazard ratio of 0.51 in time to death by hospital 
discharge or day 28 (95% CI 0.32–0.83) after adjusting for SOFA 
score and age. With treatment initiated before day 14, the number 
needed to treat (NNT) to save one life is 5.3.”
While the observed mortality benefits  –  originating from 
small-to-moderate size trials and investigating different treatment 
protocols – should be accepted with caution, concordance with the 
trial-level meta-analysis on hospital mortality (29–36) (36 vs. 49%, 
risk ratio 0.76, 95% CI 0.59–098; p = 0.035, I2 = 17%; moderate 
certainty) provides increased confidence for a survival benefit for 
those randomized before day 14 of ARDS. The benefits persist 
when the analysis includes a newly presented RCT (n = 197) (37) 
(29 vs. 44%; RR 0.62, 95% CI 0.44–0.86, p =  0.005; I2 =  46%). 
Additional support is also provided by the results of seven cohort 
studies with historical or concurrent control (n = 544) (38–43) 
reporting a significant mortality reduction (29 vs. 44%; RR 0.68, 
F-95%, CI 0.57–0.81; p <  0.001, I2 =  46%), and separate meta-
analyses showing moderate certainty in a mortality reduction and 
in prevention of ARDS in patients hospitalized with community-
acquired pneumonia (58), and high quality evidence for a mortal-
ity reduction for pneumocystis pneumonia (63).
GLUCOCORTiCOiD THeRAPY FOR 
PeDiATRiC ARDS
Besides low tidal volume ventilation (64) as part of a “lung 
protective” ventilation strategy, no other therapeutic approach 
has consistently shown improvement in the outcomes of children 
with ARDS or has routinely been implemented in our PICUs (65, 
66). Unfortunately, even the effects of low tidal volume ventila-
tion in pediatric ARDS (PARDS) are not based on adequately 
powered, randomized trials but are extrapolated from adult 
ARDS studies, single center observational studies, case reports, 
retrospective chart reviews, and pilot studies (67–70). Similarly, 
when compared to the adult literature on ARDS, our experience 
with glucocorticoid therapy for PARDS is limited. Nevertheless, 
the theoretical indications for using glucocorticoid therapy in 
PARDS are similar to those of adult ARDS. These include (1) a 
glucocorticoid receptor-mediated downregulation of systemic 
and pulmonary inflammation, which is essential for the restora-
tion of tissue homeostasis, disease resolution, and prevention of 
lung fibrosis (71), and (2) an improvement in capillary-alveolar 
barrier function, with resolution of alveolar flooding and induc-
tion of ENaC (epithelial Na channel) expression and function 
(72–74). Conversely, concerns about glucocorticoid therapy for 
children with PARDS revolve around (1) the potential for bone 
growth retardation or growth arrest (75), (2) suppression of the 
immature immune system, including a potential increase in 
nosocomial infections or worsening of an existing infection (76), 
(3) a potential for glucocorticoid-induced hyperglycemia or sys-
temic hypertension, and (4) psychiatric effects, such as insomnia 
or delirium (77–79).
Multiple reasons account for our lack of knowledge in regard 
to glucocorticoid-mediated effects in PARDS, including (1) the 
incidence of PARDS is lower than of adult ARDS [12.8 vs. 78.9 
cases per 100,000 person years (65)], (2) mortality rates from 
PARDS are lower than from adult ARDS [18 vs. 38.5% (80)], (3) 
most pediatric intensivists consider glucocorticoid therapy an 
adjunctive therapy for severe, refractory PARDS, and (4) signifi-
cant concerns persist among pediatricians regarding the potential 
adverse effects of glucocorticoids particularly on child growth 
and the immature immune system. Despite these limitations, it is 
clearly untenable to administer or withhold glucocorticoids from 
children with PARDS by simply extrapolating data from adult 
studies since the disease patterns, immunological responses, 
capacity for lung growth and development, and clinical outcomes 
of PARDS differ substantially from those of adult patients (81). 
PARDS caused by sepsis, pneumonia, and aspiration could con-
ceptually respond favorably to glucocorticoid treatment, but we 
have little information about the susceptibility or risk factors for 
PARDS resulting from such triggers.
Several recent studies have confirmed that a large proportion 
of pediatric intensivists use adjunctive treatments in deteriorating 
PARDS patients, with glucocorticoids being utilized by 30–35% 
of pediatricians (82, 83). Interestingly, a Scandinavian study from 
2015 reported that 83% of Nordic pediatricians administered 
glucocorticoids “sometimes” for PARDS patients, whereas only 
17% admitted to “never” using glucocorticoids for PARDS (84).
Martinot et  al. published the first report of glucocorticoids 
administration to children for refractory PARDS in 1997 (85). 
Six children (age 3–11 years) with moderate–severe PARDS who 
showed no improvement by days 4–17 of mechanical ventilation 
were treated with daily methylprednisolone boluses (30 mg/kg) 
for 3–6 days depending on the observed response. Glucocorticoid 
treatment was associated with significant improvements in 
oxygenation between days 1 and 5, and ultimately four of the 
six children survived. After the initial glucocorticoid bolus, 
three of the four survivors received a daily methylprednisolone 
maintenance dose of 2 mg/kg/day followed by a taper for a total 
treatment duration of 4–11 weeks. The fourth survivor did not 
receive maintenance therapy after the initial methylprednisolone 
bolus since a bacterial superinfection was suspected. Interestingly, 
none of the children sustained any glucocorticoid-related adverse 
events, including hypertension, nosocomial infections or gastro-
intestinal bleeding.
Two years later, Goh et al. reported of a 12-month-old with 
measles-associated refractory PARDS that was successfully 
treated with a 42-day course of methylprednisolone, consisting 
of 2  weeks of maintenance therapy and a 2-week taper (86). 
This protocol was based on the Meduri et  al. (31) randomized 
trial investigating prolonged methylprednisolone treatment in 
adult patients with unresolving ARDS. However, Goh used sig-
nificantly higher doses (5 mg/kg bolus, followed by 8 mg/kg/day 
maintenance) than those used in the Meduri trial (2 mg/kg bolus, 
2 mg/kg/day maintenance). Despite the relatively high glucocor-
ticoid dose, the only adverse effect noted was a fungal urinary 
tract infection, which responded to antifungal therapy and no 
other infectious, gastrointestinal, or metabolic adverse effects 
were observed. In 2006, Guglani et al. reported a 21-month-old 
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child with unresolving PARDS related to malnutrition and 
 eosinophilic gastroenteritis successfully treated with a 32-day 
course of methylprednisolone therapy (87). In contrast to Goh, 
Guglani administered a lower dose of methylprednisolone (2 mg/
kg bolus, followed by 2 mg/kg/day maintenance), similar to the 
regimen proposed in the 1998 Meduri trial (31). Importantly, this 
child also suffered no metabolic, cardiovascular, or infectious 
adverse effects or muscle weakness from glucocorticoid therapy.
Over the past two decades, it became increasingly evident 
that surfactant loss is a major contributor to the development 
and progression of adult ARDS and PARDS. Neonatologists have 
long been aware of the stimulatory effects of glucocorticoids 
on lung maturation and surfactant production, an idea that 
is well supported by animal studies. In fact, in young rats with 
lipopolysaccharide-induced acute lung injury, early administra-
tion of dexamethasone (5 mg/kg) increased surfactant protein D 
levels (88). It seems plausible from this and other studies that 
glucocorticoids could have similar surfactant-stimulatory effects 
in PARDS. Although Willson et al. initially found a survival ben-
efit in PARDS patients treated with surfactant (89), this effect was 
not confirmed in a later study (90). In a surfactant-deficient acute 
lung injury model, dexamethasone combined with surfactant 
administration conveyed no additional benefit over surfactant 
administration alone, despite decreasing nuclear NF-κB levels 
in lung homogenates (91). The surfactant-stimulating effects of 
glucocorticoids are well known in neonates, but a link between 
glucocorticoid administration and improved surfactant levels in 
PARDS has never been shown. Of interest, the ARDS network 
reported that patients randomized to the methylprednisolone 
vs. placebo group had an increased ratio of functional large 
surfactant aggregates to dysfunctional small aggregates in their 
cell-free supernatants (28).
While recognizing the difficulties of performing adequately 
powered RCTs in children, determining the utility of glucocorti-
coids in PARDS remains a high priority for pediatric intensivists. 
In 2015, Drago et al. used for the first time a double-blinded RCT 
design in a pilot study demonstrating the feasibility of adminis-
tering prolonged, low-dose glucocorticoids and measuring clini-
cally relevant outcomes in children with early PARDS (59). In the 
35 patients randomized to placebo or glucocorticoid groups, no 
differences occurred in duration of mechanical ventilation, ICU 
stay, hospital stay, or mortality. However, the glucocorticoid 
group had higher PaO2/FiO2 ratios on days 8 and 9 and lower 
CO2 levels on days 2 and 3 of treatment, required fewer racemic 
epinephrine treatments for post-extubation stridor and less sup-
plemental oxygen at PICU discharge. Importantly, glucocorticoid 
treatment (a single 2  mg/kg IV methylprednisolone bolus, fol-
lowed by 7 days of 1 mg/kg/day methylprednisolone maintenance 
therapy and a 7-day taper) was not associated with any adverse 
effects, such as hyperglycemia or nosocomial infections. The 
strengths of this study included the enrollment of a generalizable 
PICU population, a randomized placebo-controlled study design, 
masked study drug infusions, a standardized regimen of low-dose 
methylprednisolone, a priori definition of primary and second-
ary outcomes and of potential adverse drug effects, as well as an 
intention-to-treat analysis with complete follow-up of all enrolled 
subjects. Limitations of this study included the relatively small 
sample size (17 and 18 patients in the glucocorticoid and placebo 
groups, respectively) and failure to strictly standardize ventila-
tor management and ventilator weaning strategies. Although a 
2-week glucocorticoid course can be considered as “prolonged” 
treatment and has been used in several adult ARDS trials, the 
most prominent benefits in the adult studies occurred with a 
4-week course of glucocorticoids (58). Furthermore, although 
this exploratory study demonstrated the feasibility of prolonged 
glucocorticoid infusions in PARDS patients without any obvious 
adverse effects, a proper safety analysis could not be performed 
with this sample size.
Later in 2015, the same authors published a follow-up study 
describing alterations in plasma biomarkers in PARDS patients 
and associations of these biomarkers with the changes in clinical 
outcomes observed earlier (92). Interestingly, the placebo group 
showed higher IL-15 and basophil levels at study entry, whereas 
on day 7 this group showed lower IL-1α, IFN-γ, and IL-10 levels. 
In contrast, the glucocorticoid group showed lower INF-α, IL-6, 
IL-10, MCP-1, G-CSF, and GM-CSF levels at study entry, but 
higher IL-17α levels on day 7. Total and differential cell counts 
remained unchanged within the placebo group between days 
0 and 7, whereas in the glucocorticoid group, total WBC and 
platelets counts were increased on day 7 (92). The authors also 
proposed a series of positive and negative correlations between 
cytokine levels, cell counts, coagulation parameters, and clinical 
parameters of disease severity. Although inflammatory biomark-
ers can be successfully measured in PARDS patients with com-
mercially available techniques, limitations of this study include 
again the small sample size (35 patients), the relatively short study 
period of 7 days, the inability to compare plasma to BAL samples 
(an intrinsic problem for most pediatric studies of lung disease), 
and the lack of functional assays to uncover any mechanistic 
consequences of these alterations in biomarkers.
In the same year, Yehya et al. published a prospective, obser-
vational single center study of 283 PARDS patients describing the 
association between glucocorticoid exposure for >24 h and the 
clinical outcomes of these patients (93). Interestingly, similar to 
the Scandinavian survey, the majority (60%) of PARDS patients 
in this US-based study received glucocorticoids for >24 h and 
only 23% did not receive any type of glucocorticoid. However, 
the glucocorticoid most commonly used was hydrocortisone 
and not methylprednisolone, the most commonly adminis-
tered glucocorticoid in large-scale, adult ARDS trials showing 
improvements in outcomes. Yehya et  al. found that all-type 
glucocorticoid exposure for >24 h was associated with increased 
mortality in PARDS, fewer ventilator-free days at 28 days, and 
longer duration of mechanical ventilation in survivors, although 
after multivariate and propensity score adjustments, the increase 
in mortality was no longer detectable. Strengths of this study 
include the larger sample size and meticulous documentation 
of all types of glucocorticoid exposures. The study also revealed 
that currently pediatricians use multiple types of glucocorticoids 
for PARDS patients and for a variety of indications, with shock 
ranking as the most common. However, the outcomes of this 
study stand in marked contradiction to multiple, large-scale, and 
highly powered, randomized adult ARDS trials, which consist-
ently show improvements in clinical outcomes and inflammatory 
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biomarkers. This discrepancy may be explained by several 
limitations of the Yehya study, including (1) not recording the 
specific indication for glucocorticoid administration, (2) group-
ing unexposed and short-term (<24 h) glucocorticoid-exposed 
patients together as a control group, and (3) no implementa-
tion of a glucocorticoid weaning protocol to prevent rebound 
inflammation, which is a key feature of the adult, glucocorticoid-
favoring ARDS trials. These flaws create major challenges in the 
interpretation of the data and in assigning clinical relevance to 
these findings.
Clearly, much more research is needed before we can make 
an educated decision about the use of glucocorticoids for all, 
or even some, PARDS patients. Nevertheless, most recently 
the expert panel of the 2015 Pediatric Acute Lung Injury 
Consensus Conference recommended with “strong agree-
ment” against the use of glucocorticoid therapy for PARDS. 
These experts highlighted the need for future research to 
identify specific pediatric patient populations most likely 
to benefit from glucocorticoid therapy and encouraged the 
development of pediatric dosing and delivery regimens (94). 
Another expert review proposed that ARDS patients with 
adrenocortical insufficiency would demonstrate greater 
benefit with glucocorticoids as compared to patients with an 
intact hypothalamic–pituitary–adrenal axis (95).
FUTURe ReSeARCH PRiORiTieS
 1. The relatively low incidence and mortality rates from 
PARDS in comparison to adult ARDS mandate the careful 
design of a large, multicenter RCT to determine the effects 
of prolonged glucocorticoid therapy on PARDS outcomes, 
such as mortality, duration of mechanical ventilation, 
ICU-free days, or hospital stay, since a single center study 
is unlikely to achieve adequate power. Drago et al. calcu-
lated that in order to achieve a 15, 28, or 36% reduction in 
the duration of mechanical ventilation, we need to enroll 
547, 137, or 98 subjects, respectively, in the placebo and 
the treatment groups (assuming an α-error of 0.01 and a 
power of 80%) (59). The design of this study should aim at 
standardizing not only the glucocorticoid protocol but also 
the mechanical ventilation and ventilator weaning proto-
cols, as well as sedation, fluid management, and nutrition 
strategies.
 2. Although it is safe to assume that patients with different 
PARDS etiologies will respond differently to prolonged glu-
cocorticoid therapy, an initial trial should enroll all patients 
who meet PARDS criteria based on the 2015 Pediatric Acute 
Lung Injury Consensus Conference (94). Stratification of 
enrollment according to their PARDS etiologies will allow a 
balanced distribution of PARDS etiologies in the treated and 
untreated groups, as well as subgroup comparisons of glu-
cocorticoid effectiveness for different subpopulations within 
these strata.
 3. Efforts to define the side effects and safety profile of prolonged, 
low-dose glucocorticoid administration should receive a 
high priority. While Drago et  al. showed the feasibility of 
administering prolonged glucocorticoid infusions to children 
with PARDS using a randomized, double-blinded study 
design, due to the relatively low number of patients enrolled, 
a safety analysis could not be performed, which needs to be 
assessed in futures studies.
 4. The molecular and clinical consequences of potential rebound 
effects after glucocorticoid discontinuation are unknown in 
children with PARDS. In the adult ARDS trials, a prolonged 
glucocorticoid weaning protocol was required to sustain 
improved outcomes. In contrast, rapid discontinuation of 
glucocorticoids, including in the ARDSnet trial, consistently 
led to increased readmission rates to the ICU, reinstitution 
of mechanical ventilation, and increased mortality (31, 96). 
It is unknown whether clinical deterioration after abrupt 
glucocorticoid discontinuation holds true for children with 
PARDS.
 5. In both adult and pediatric ARDS trials, prolonged gluco-
corticoid treatment was not associated with increased risk of 
nosocomial infections. Other glucocorticoid-induced adverse 
effects, such as hyperglycemia and hypertension, are rarely 
reported and easily controlled. Nevertheless, the effects of 
prolonged glucocorticoid therapy on the immune response of 
chronically immunosuppressed children (such as solid organ 
and bone marrow recipients) or children with autoimmune 
diseases remain unknown. In addition, we need to determine 
the effects of glucocorticoid therapy for PARDS on children 
who are chronically exposed to glucocorticoids but not 
immunosuppressed in the classical sense [e.g., inhaled gluco-
corticoids for long-term asthma or cystic fibrosis control, or 
nasal glucocorticoids for allergic rhinitis (97)].
 6. Many pediatricians are concerned about the long-term 
consequences of prolonged glucocorticoid exposure on 
bone growth and child development. The widespread use of 
short-term glucocorticoid bursts (e.g., for status asthmaticus 
or acute adrenal crisis) does not appear to affect long-term 
growth. On the other hand, exposure to inhaled or oral 
glucocorticoids for months to years (e.g., asthma control 
therapy) may decrease the growth potential of children (79). 
Significant negative effects on bone growth after glucocorti-
coid exposure for 2 weeks, as proposed in the study design 
by Drago et al. (59), is unlikely to affect the final height of 
children, but this needs to confirmed. In contrast, the adult 
ARDS trials recommend glucocorticoid therapy for 4 weeks 
(96), potentially carrying greater risk for growth-related 
long-term effects. Interestingly, critically ill children who 
suffered burn wounds actually show an increase in lean body 
mass, bone mineral content, and bone mineral density after 
prolonged exposure to synthetic glucocorticoids (98). These 
findings should encourage us to consider different types of 
glucocorticoids for PARDS therapy in order to minimize 
potential adverse effects.
 7. The consequences of a prolonged glucocorticoid course on the 
effectiveness of routine vaccinations and vaccination catch-up 
schedules are unknown and need to be determined.
 8. Dysregulated acute and chronic systemic inflammation is 
associated with long-term systemic morbidity in ARDS 
survivors, including muscle weakness with impaired physical 
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function (99) and neurocognitive impairment (100). PARDS 
RCTs must include long-term follow-up evaluating functional 
status and cognitive function.
In summary, although a robust body of adult literature points 
toward improved outcomes of ARDS patients treated with pro-
longed glucocorticoid regimens, including a slow, standardized 
glucocorticoid wean, the relative lack of pediatric data should 
encourage us to maintain equipoise toward glucocorticoid 
therapy for PARDS. We should neither assume that the adult 
results can be directly applied to a pediatric population, nor 
should we propagate generalized statements that all exposures to 
glucocorticoids, including a 4-week treatment course for PARDS, 
will increase the risk of nosocomial infections, cause hyperten-
sion, hyperglycemia, or growth retardation, since this is neither 
supported by the adult nor pediatric literature on glucocorticoid 
use in ARDS. Clearly, there is an urgent need for large-scale, well-
designed RCTs in Pediatrics to determine the role of prolonged 
glucocorticoid therapy for PARDS.
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